All three are true at once
:BIAX866498 : : , , V : 10 : () : : : : V :2 :1 10 2400
10.1007/s12264-018-0269-8 151 WhittleB
Proposed Mechanism Pathway: BPC-157 NO System Modulation Vascular Homeostasis / VEGF/VEGFR2 Upregulation Akt-eNOS Activation Angiogenesis / FAK-Paxillin Activation Cell Migration (40% increase) / EGR-1 Upregulation Growth Factor Sensitivity Tissue Regeneration Comparative Profile: RESEARCH APPLICATIONS Wound Healing Models: Extensively studied across all three healing phases

Key selective action features: No Growth Hormone Receptor Binding: Does not activate GH receptors responsible for IGF-1 stimulation and systemic growth effects Preserved Glucose Metabolism: No impact on blood sugar regulation, insulin sensitivity, or diabetic risk markers No Tissue Growth Effects: Does not promote muscle hypertrophy, organ growth, or cell proliferation pathways Adipose-Specific Targeting: Works primarily through beta-3 adrenergic receptors concentrated in fat tissue No IGF-1 Elevation: Clinical trials confirmed no changes in serum IGF-1 levels at therapeutic doses Isolated Lipolytic Action: Maintains the fat-breaking properties of growth hormone fragment 176-191 without broader effects Selective Mechanism: Structural differences from full-length GH prevent binding to receptors mediating non-fat-related effects Clinical Validation: Human studies in 900+ participants confirmed selective fat metabolism without systemic hormonal changes The following guide provides detailed analysis of AOD-9604 s selective action and why this selectivity matters for safe, targeted fat metabolism

Tesamorelin 10 mg GHRH analogue used in growth-hormone-axis research